Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant a randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 312, Issue 14, 2014, Pages 1409-1419

  Mulligan, Mark J ^a,b   Bernstein, David I ^c   Winokur, Patricia ^d,e   Rupp, Richard ^f   Anderson, Evan ^b   Rouphael, Nadine ^b   Dickey, Michelle ^c   Stapleton, Jack T ^d,e   Edupuganti, Srilatha ^b   Spearman, Paul ^b   Ince, Dilek ^d,e   Noah, Diana L ^g   Hill, Heather ^h   Bellamy, Abbie R ^h   Mask, Karen ^a   Beck, Allison ^a   Lai, Lilin ^a   Rimann, Nayoka ^a   Kelley, Colleen ^a   Ogilvie, Melinda ^a   Osinski, Eileen ^a   Battle, Dawn ^a   Camacho Gonzalez, Andres ⁱ   McElroy, Anita ⁱ   Shane, Andi ⁱ   Anderson, Larry ⁱ   Stephens, Kathy ⁱ   Hartwell, Brooke ⁱ   Ball, Teresa ⁱ   Hussani, Laila ⁱ   Gibson, Theda ⁱ   Johnson, Melanie ⁱ   Sederdahl, Bethany ⁱ   Mann, Natasha ⁱ   Frenck, Robert ^j   Brady, Rebecca ^j   Foltz, Tara ^j   Cline, Amy ^j   McCartney, Sarah ^j   Huron, Margery ^j   Meier, Jeffrey ^d   Schilling, Margo ^d   Wagner, Nancy ^d   Dull, Geraldine ^d   Flanders, Kathy ^d   Zhao, Dan ^d   Reidy, Mary ^d   Cress, Gretchen ^d   Gerot, Nikki ^d   Barrett, Diane ^f   Harrington, Carrie ^f   McMahan, Amy ^f   Shafer, Marianne ^f   Simon, Lori ^f   Taggart, Barbara ^g   Johnson, Valerie ^g   Bowen, Donna ^g   Li, Shixiong ^g   Looney, Candi ^g   May, Megan ^g   May, Rachel ^g   Parker, Lawanda ^g   Myers, Bridgette ^g   Cochran, Nertaissa ^g   Bell, Michelle ^g   Haller, Logan ^g   Stablein, Claire ^h   Marshall, Sara ^h   McDonough, Megan ^h   He, Fenhua ^h   Guo, Kuo ^h   Lambert, Linda ^k   Buchanan, Wendy ^k   Riddle, Valerie ^k   Murray, Suzanne ^k   Gorman, Richard ^k   more..

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g SOUTHERN RESEARCH INSTITUTE   (United States)

^h EMMES CORPORATION   (United States)

ⁱ Emory Children's Pediatric Institute   (United States)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^k National Institute of Allergy   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MIFAMURTIDE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIGEN;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H7N9; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; UNSPECIFIED SIDE EFFECT; VACCINATION REACTION; ANTIBODY PRODUCTION; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA; METHODOLOGY; MIDDLE AGED; VACCINATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84907698232     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.12854     Document Type: Article

References (45)

1. Li Q, Zhou L, Zhou M, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med. 2014;370(6):520-532.
2. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277-2285.
3. Qi X, Qian YH, Bao CJ, et al. Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ. 2013;347:f4752.
4. World Health Organization. WHO risk assessment of human infection with avian influenza A(H7N9) virus: WHO risk assessment as of 27 June 2014. http://www.who.int/entity/influenza/human-animal-interface/influenza-h7n9/Risk-Assessment/en/index.html. Accessed September 1, 2014.
5. Uyeki TM, Cox NJ. Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med. 2013;368(20):1862-1864.
6. Zhu H, Wang D, Kelvin DJ, et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science. 2013;341(6142):183-186.
7. US Centers for Disease Control and Prevention. Avian influenza A virus infections of humans, 2003. http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm. Accessed March 22, 2014.
8. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101(5):1356-1361.
9. Couch RB, Patel SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012;7(12): e49704.
10. Podda A. The adjuvanted influenza vaccines with novel adjuvants. Vaccine. 2001;19(17-19):2673- 2680.
11. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008;197(5):667-675.
12. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365(15):1406-1416.
13. Pellegrini M, Nicolay U, Lindert K, et al. MF59-adjuvanted versus non-adjuvanted influenza vaccines. Vaccine. 2009;27(49):6959-6965.
14. Ng S, Fang VJ, Ip DK, et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 2013;208(8):1320-1324.
15. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond). 1972; 70(4):767-777.
16. Noah DL, Hill H, Hines D, White EL, Wolff MC. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol. 2009;16(4):558-566.
17. Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the US pandemic preparedness plan in 2009. Vaccine. 2012;30(28):4240-4248.
18. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Heart, Lung, and Blood Institute; 1998.
19. US Food and Drug Administration. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines, 2007. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf. Accessed May 3, 2014.
20. Couch RB, Decker WK, Utama B, et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One. 2012;7(12): e50830.
21. Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine. 2009;27(28):3744-3753.
22. Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009;27(13):1889-1897.
23. Osterholm MT, Ballering KS, Kelley NS. Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). JAMA. 2013;309(24):2557-2558.
24. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res. 2013;178(1):78- 98.
25. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354(13):1343-1351.
26. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine. Lancet. 2001;357(9272):1937-1943.
27. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines. J Infect Dis. 2010;201(11):1644- 1653.
28. Davenport FM, Hennessy AV, Francis T Jr. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med. 1953;98(6):641-656.
29. Beyer WE, de Bruijn IA, Palache AM, et al. The plea against annual influenza vaccination? Vaccine. 1998;16(20):1929-1932.
30. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56(10):1363-1369.
31. Treanor JJ, Szilagyi P. Editorial commentary: Influenza vaccine: glass half full or half empty? Clin Infect Dis. 2013;56(10):1370-1372.
32. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season. Clin Infect Dis. 2014;58(3):319-327.
33. Neuzil KM, Victor JC. Annual studies of influenza vaccine effectiveness. Clin Infect Dis. 2014;58(3):328-329.
34. Sasaki S, He XS, Holmes TH, et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One. 2008;3(8):e2975.
35. He XS, Holmes TH, Sasaki S, et al. Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One. 2008;3(7):e2574.
36. Frey SE, Bernstein DI, Gerber MA, et al. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. J Infect Dis. 2012; 206(6):828-837.
37. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: A randomized trial. JAMA. 2010;303(1):37-46.
38. Nolan T, Richmond PC, Formica NT, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine. 2008;26(50):6383- 6391.
39. Kim JH, DavisWG, Sambhara S, Jacob J. Strategies to alleviate original antigenic sin responses to influenza viruses. Proc Natl Acad Sci U S A. 2012;109(34):13751-13756.
40. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009; 200(2):172-180.
41. Poland GA, Mulligan MJ. The imperative of influenza vaccines for elderly individuals-an evolving story. J Infect Dis. 2009;200(2):161-163.
42. McElhaney JE, Beran J, Devaster JM, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people. Lancet Infect Dis. 2013;13(6):485-496.
43. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis. 2011;52 (3):301-312.
44. Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013;369(26):2564-2566.
45. Bart SA, Hohenboken M, Della Cioppa G, et al. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med. 2014;6(234):34-55.